Clinical trials: Obesity Overweight
Overweight, Obesity
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections.
- Trial name
- NCT07605052
- Testing
- Cagrilintide B, Cagrilintide D
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Novo Nordisk A/S
Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
- Trial name
- NCT06548100
- Testing
- mibavademab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight, Obesity
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
- Trial name
- NCT07523711
- Testing
- COC, Maridebart Cafraglutide
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Amgen
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
- Trial name
- TRIUMPH-8 (NCT07232719)
- Testing
- Retatrutide
- Where
- 31 sites in United States, United Kingdom
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Overweight and/or Obesity, Weight Management
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
- Trial name
- NCT07243171
- Testing
- ecnoglutide tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Overweight, Obesity
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight.
- Trial name
- OASIS 3 (NCT05890976)
- Testing
- Semaglutide
- Where
- 16 sites in China
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Bariatric Surgery, Obesity
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).
- Conditions
- Bariatric Surgery, Obesity, Weight Gain
- Trial name
- NCT05215847
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Aardvark Therapeutics, Inc.
Obesity
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors.
- Trial name
- NCT06780449
- Testing
- Cagrilintide, Semaglutide
- Where
- 36 sites in United States, Belgium and 4 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Evaluate the Safety and Tolerability, Healthy and Overweight or Obese Participants
Phase 1 Study of Ascending Doses of CMS-D008 in Healthy and Overweight/Obese Adults
This study is a first-in-human clinical trial of CMS-D008 conducted in Chinese healthy and overweight or obese adult participants, consisting of three parts: Part-1 Single Ascending Dose (SAD) study (hereinafter referred to as…
- Trial name
- NCT07518589
- Testing
- CMS-D008
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Obesity, Dyslipidemia
Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia
Primary objective: to assess the effect of AVE1625 on weight loss over a period of 24 weeks in abdominally obese patients with atherogenic dyslipidemia.
- Trial name
- NCT00345410
- Testing
- AVE1625 B
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Sanofi
Overweight or Obesity
Examination of Circumferential Reduction
The rationale for the selection of Outcome Measures is the compliance with FDA regulations as pertain to medical devices with a moderate level of risk of hazard leading to harm of the patient; firstly, the safety of the device in…
- Trial name
- NCT04451824
- Testing
- CL-100
- Where
- 3 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Contour Research
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Truway Diagnostic Tools in Primary Care
This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings.
- Conditions
- Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute
- Trial name
- TruDxPC (NCT07209527)
- Testing
- Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Truway Health, Inc.
Obesity, Morbid
Early Feasibility Study: Assessment of Self-Forming Magnetic Anastomosis Device and Delivery System (SFM) in Obese Patients, When Used to Create a Duodenal-Ileal Anastomosis Post SG (SNAP-PS), or Used to Create a Jejuno-Jejunal (J-J) Anastomosis
The objectives of this study are to assess the initial safety and device functionality of the SFM Anastomosis System including delivery systems when used to create a duodenal-ileal (D-I) anastomosis with patients with prior…
- Trial name
- GIW-J-J (NCT06200896)
- Testing
- Self Forming Magnets used to Create A Compression Anastomosis
- Where
- Chile
- Volunteers
- 28 people
- Sponsor
- GI Windows, Inc.
Obesity
RESCUE: Discontinuation of GLP-1
This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.
- Trial name
- NCT07190794
- Testing
- OverStitch™ or OverStitch NXT™, Lifestyle Modification
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
Overweight, Obesity
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe.
- Trial name
- NCT07357766
- Testing
- Cagrisema
- Where
- 116 sites in United States, Bulgaria and 12 more
- Sponsor
- Novo Nordisk A/S
Haemophilia A, Haemophilia B, Obesity
Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)
An online web-based cross-sectional survey in which participants will complete a distinct questionnaire for patients with hemophilia and obesity (PwHO) and/or their carers/spouses/partners, or a distinct questionnaire for…
- Trial name
- ACTION to HOPE (NCT03430154)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Novo Nordisk A/S
Obesity
Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study
This research study is being performed to find out if a new device, AspireAssist Aspiration Therapy System, can help people with obesity to lose weight without causing too many side effects.
- Trial name
- PATHWAY (NCT01766037)
- Testing
- Aspiration Therapy (AspireAssist), Lifestyle Therapy
- Where
- 10 sites in United States
- Volunteers
- 171 people
- Sponsor
- Aspire Bariatrics, Inc.
Obesity or Overweight
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
The study is investigating weight loss and treatment patterns associated with the use of Saxenda® in adult patients. The aim of the study is to assess the weight loss associated with Saxenda® in patients with obesity or…
- Trial name
- NCT05153590
- Testing
- Saxenda®
- Where
- Denmark
- Volunteers
- 269 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients
evaluation of the EndoZip system procedure compared to the Apollo ESG procedure in obese patients.
- Trial name
- ESG (NCT07090005)
- Testing
- EndoZip System, OverStitch Endoscopic Suturing System (ESG)
- Where
- 5 sites in United States, Italy
- Volunteers
- 184 people
- Sponsor
- Nitinotes Surgical Ltd.
Overweight or Obesity
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.
- Trial name
- NCT06396429
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 567 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.